EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Merkel Cell Polyomavirus—Pathophysiology and Treatment in the Era of Gene‐Targeted Therapies

Trairong Chokwassanasakulkit iD, Nigel A J McMillan iD

Reviews in Medical Virology · 2024

DOI: 10.1002/rmv.2580 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Reviews in Medical Virology, 2024. Verfasst von Trairong Chokwassanasakulkit und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedicine and Glycomics and School and Pharmacy and Medical Sciences, Griffith University, Gold Coast, Australia. Hauptthemen laut MEDLINE: Merkel cell polyomavirus, Carcinoma, Merkel Cell, Polyomavirus Infections, Genetic Therapy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Griffith University, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Merkel cell polyomavirus (MCPyV) is a significant contributor to the development of Merkel cell carcinoma (MCC), an aggressive skin cancer with high recurrence and a low survival rate. In fact, it is the deadliest skin cancer. The precise routes of transmission for MCPyV‐positive MCC remain unclear, but several factors may trigger its development. Conventional treatments for MCC are not highly effective, especially in patients with metastasis, with a clear need for new treatment options. Gene‐targeted therapies hold great promise for the treatment of MCC, including the use of siRNA and CRISPR/Cas (C/Cas) but critically none have yet been translated into clinical trials. Validating this approach is the fact that several siRNA products are already FDA licenced, while C/Cas has entered clinical trial, albeit for conditions other than MCC. There are many challenges that must be overcome to move from preclinical research to the clinic. In this review, we provide a comprehensive summary of the current understanding of MCC, with a particular focus on MCPyV‐positive MCC, and the status of gene‐targeted therapies. Additionally, we discuss the major obstacles that impede MCC research and explore future prospects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Merkel cell polyomavirusCarcinoma, Merkel CellPolyomavirus InfectionsGenetic TherapyHumansSkin NeoplasmsAnimalsTumor Virus InfectionsRNA, Small Interfering

Stichwörter der Autor:innen

C/CasMerkel cell carcinoma (MCC)Merkel cell polyomavirus (MCPyV)gene‐targeted therapysiRNA

Substanzen

RNA, Small Interfering

Autor:innen und Institutionen

  • Institute of Biomedicine and Glycomics and School and Pharmacy and Medical Sciences, Griffith University, Gold Coast, Australia.

ORCID-Profile: Trairong Chokwassanasakulkit, Nigel A J McMillan

Förderung

  • Griffith University
  • National Health and Medical Research Council

Zitieren

APA

Chokwassanasakulkit, T., & McMillan, N. A. J. (2024). Merkel Cell Polyomavirus—Pathophysiology and Treatment in the Era of Gene‐Targeted Therapies. Reviews in Medical Virology. https://doi.org/10.1002/rmv.2580

Vancouver

Chokwassanasakulkit T, McMillan NAJ. Merkel Cell Polyomavirus—Pathophysiology and Treatment in the Era of Gene‐Targeted Therapies. Reviews in Medical Virology. 2024. doi:10.1002/rmv.2580

BibTeX
@article{Chokwassanasakulkit2024,
  author = {Chokwassanasakulkit, Trairong and McMillan, Nigel A J},
  title = {Merkel Cell Polyomavirus—Pathophysiology and Treatment in the Era of Gene‐Targeted Therapies},
  journal = {Reviews in Medical Virology},
  year = {2024},
  doi = {10.1002/rmv.2580}
}
Kostenlos starten →